ERBB2 and neoplasm: Multivariate analysis, based on the expression of at least one of the following four profiles: CK-19, and/or CD44high/CD24low, and/or ALDH1high/CD24low and and/or HER2 independently from patients’ age, tumor T stage, grade, nodal status, and the receptor status (ER, PR, HER2) of the primary tumor confirmed also the prognostic value of gene expression in EpCAM(+) CTCs (p = 0.002) (Table 2).